
Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology

II. Safety

E.G. Favalli¹, R. Caporali², L. Sinigaglia³, N. Pipitone⁴, I. Miniati⁵,
C. Montecucco², M. Matucci-Cerinic⁵

¹Division of Rheumatology, University of Milan, Istituto Ortopedico G. Pini, Milano, Italy; ²Division of Rheumatology, University of Pavia, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy; ³Department of Rheumatology, Struttura Complessa di Reumatologia DH, Istituto Ortopedico G. Pini, Milano, Italy; ⁴Department of Rheumatology, Arcispedale Santa Maria Nuova, Reggio Emilia, Italy; ⁵Department of Biomedicine, Division of Rheumatology, DENOTHE Centre, University of Florence, Florence, Italy.
Ennio G. Favalli, Roberto Caporali, Luigi Sinigaglia, Nicolò Pipitone, Irene Miniati, Carlomaurizio Montecucco, Marco Matucci-Cerinic.

Please address correspondence to:
Roberto Caporali, MD,
UOC Reumatologia,
IRCCS Policlinico S. Matteo,
Piazzale Golgi 2,
27100 Pavia, Italy.
E-mail: caporali@smatteo.pv.it

Received on May 24, 2011; accepted in revised form on June 14, 2011.

Clin Exp Rheumatol 2011; 29 (Suppl. 66): S15-S27.

© Copyright CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 2011.

Key words: rheumatoid arthritis, biologic therapy, safety

Competing interests: R. Caporali has received honoraria as a speaker from Abbott, BMS and Roche; C. Montecucco has received grants and research support from Abbott, Merck Sharp and Dohme, Pfizer, Schering-Plough, and Roche; the other co-authors have declared no competing interests.

ABSTRACT

Given the availability of novel biologic agents for the treatment of rheumatoid arthritis (RA), various national scientific societies have developed specific recommendations in order to assist rheumatologists in prescribing these drugs. The Italian Society for Rheumatology (Società Italiana di Reumatologia, SIR) decided to update its recommendations, and, to this end, a systematic literature review was performed and the evidence derived from it was discussed and summarised as expert opinions. Levels of evidence and strength of recommendations were reported. The recommendations reported refer to the safety of biologic agents and are intended to help prescribing rheumatologists to optimise the use of biologic agents in patients with RA seen in everyday practice; they are not to be considered as a regulatory rule.

Introduction

Biologic therapies have had a profound impact on the treatment of patients with rheumatoid arthritis (RA); However, safety concerns have emerged after their use in everyday practice and specific recommendations have been published by different rheumatologic societies in order to minimise possible adverse events.

The Italian Society for Rheumatology (Società Italiana di Reumatologia, SIR) has previously published a set of recommendations for the use of anti-TNF therapies in RA (1), which included safety issues, and now presents an update taking into account data from randomised controlled studies (RCTs) and data coming from large national registries. In this paper we will focus on the safety of biologic treatments, presenting recommendations on the main issues raised from more than 10

years of biologic treatment use in everyday clinical practice (2). The evidence coming from the literature was discussed and summarised as recommendations, with level of evidence, strength of recommendation as well as level of agreement clearly stated.

Autoimmunity

The new appearance of circulating autoantibodies, such as antinuclear (ANA), anti-phospholipid and anti-double-stranded DNA antibodies (anti-dsDNA) is a common finding during the administration of TNF blocking agents (particularly monoclonal antibodies) as reported both in main RCTs, (level of evidence 1B) (3-6)) and in observational studies (level of evidence 2B) (7-12). ANA and anti-dsDNA become positive respectively in up to 40% and 25% of patients treated with infliximab (13) and in up to 12% and 11% of those treated with adalimumab (14). However, related clinical autoimmune syndromes (anti-phospholipid and lupus-like mainly) are rare and reversible after anti-TNF therapy withdrawal (level of evidence 3b and 4) (15-22). No increased incidence of autoimmune diseases was reported in the abatacept clinical trial database (level of evidence 1a) (23). No evidence of autoimmunity during therapy with rituximab and anakinra has been published.

Recommendations

- ANA positivity does not contraindicate treatment with biological agents (grade of recommendation B).
- ANA and anti-dsDNA formation during anti-TNF treatment in the absence of clinical syndromes does not preclude the continuation of the treatment (grade of recommendation B).
- In the case of a new-onset clinical

autoimmune syndrome during anti-TNF treatment, withdrawal of biological agent is recommended (grade of recommendation C).

Injection site/infusion reactions

Injection site reactions (ISRs, consisting of localised erythema, itching, pain or swelling) with subcutaneous TNF blockers in RCTs have been reported to be more common in treated patients (up to 26% of patients with adalimumab and 21% with etanercept) than with placebo, and were generally mild to moderate and only in rare cases resulted in drug discontinuation (level of evidence 1b) (5, 14, 24).

Acute reactions (within 24 hours) with intravenous infliximab are reported with an incidence between 4% and 21% of patients and were generally mild to moderate, even if serious reactions (such as anaphylactoid manifestations) have been reported in rare cases (level of evidence 1b) (13, 25). Occasionally, delayed forms of reaction may occur as a serum sickness-like illness (level of evidence 4) (26). The presence of human anti-chimeric antibodies (HACA) against infliximab may increase the incidence of infusion reactions (level of evidence 3a) (27). Low-dose daily corticosteroids were reported to be associated with a significantly lower risk for a treatment-limiting infusion reaction (level of evidence 2b) (28), whereas intravenous corticosteroids pretreatment may reduce HACA formation (level of evidence 2b) (29), but do not decrease the incidence and severity of infusion reactions (level of evidence 1b) (30). Moreover, shortened infliximab infusion time does not seem to compromise safety if initial infusions are well tolerated (level of evidence 2b) (31). Infliximab infusion reactions may be treated by slowing the infusion rate or by the administration of corticosteroids and/or antihistamines (level of evidence 2b) (32).

Rituximab acute infusion reactions (generally mild to moderate) are common and more frequent after the first infusion of each course (up to 38%, level of evidence 1b) (33, 34). Rarely, delayed serum sickness-like reactions may occur (level of evidence 4) (35).

Infusion reactions can be reduced and managed by premedication with an antihistamine, acetaminophen, and corticosteroids, or by slowing the rate of infusion (level of evidence 1a) (36).

Acute infusion reactions with abatacept are uncommon (less than 10% of patients) and mostly mild to moderate in intensity (level of evidence 1b) (37-39). Considering RCTs pooled safety data, less than 1% of patients experienced severe hypersensitivity reactions, including two cases of anaphylaxis or anaphylactoid reactions (level of evidence 1a) (40).

In main RCTs with anakinra, ISRs are the most commonly reported adverse event, occurring in up to 70% of patients (level of evidence 1b) (41, 42). Most ISRs are of mild or moderate severity and are transient in nature, but represent the most common event leading to anakinra withdrawal in clinical practice (level of evidence 2b) (40).

Recommendations

- When a severe infusion reaction occurs with any iv biological agent, infusion must be stopped and treatment with corticosteroids and/or antihistamines should be considered (grade of recommendation B).
- Mild to moderate infusion reactions with any iv biological agent may be treated by slowing infusion rate or by the administration of corticosteroids and/or antihistamines (grade of recommendation B).
- When a severe/moderate infusion reaction is experienced with any iv biological drug, switch to another agent is recommended (grade of recommendation D).
- Premedication with antihistamines, acetaminophen (paracetamol), and corticosteroids is mandatory before rituximab infusions, whilst it seems ineffective in reducing reaction frequency and severity in infliximab treated patients (grade of recommendation A).

Infections

Tuberculosis

TNF- α is a key cytokine in protecting host defence against Mycobacterium tuberculosis and, together with

TNF-dependent chemokines, plays an important role in the development and maintenance of the granuloma (level of evidence 1b) (44, 45). Thus, TNF inhibition can increase the susceptibility to mycobacteria and particularly can promote the reactivation of latent tuberculosis infection (LTBI) in previously exposed patients (46).

Several spontaneous case presentations and observational studies (mainly based on national registries) have reported an increase in active tuberculosis infections (ATBI) associated with the use of TNF antagonists (level of evidence 4) (47-50). The majority of cases occurred shortly after starting anti-TNF therapy, suggesting a reactivation of LTBI; nevertheless, delayed cases consistent with new infection have occasionally been reported (level of evidence 4) (51). Clinical manifestation of anti-TNF-related ATBI may be often atypical, such as miliary or extrapulmonary presentation (level of evidence 4) (50). Differences among TNF blockers with respect to mechanism of action, pharmacokinetics or biology suggests the possibility of a different risk for granulomatous infections (52). Recent data from observational studies showed a higher risk of ATBI associated with monoclonal antibodies than with etanercept (level of evidence 2b) (53, 54). Nevertheless, in the absence of head-to-head comparisons among anti-TNF agents, an increased susceptibility to ATBI has to be intended as a class effect to date.

A recently published survey highlighted the increasing incidence of non-tuberculous mycobacterial infections (up to 50% Mycobacterium Avium) in TNF blocker treated patients (level of evidence 4) (55).

To address concerns about increased susceptibility to ATBI or reactivation of LTBI, screening for tuberculosis must be performed before beginning therapy with anti-TNF agents. In accordance to local guidelines, screening for LTBI should include: a tuberculin skin test (TST, with positive result >5 mm), a chest radiograph (showing evidence of past tuberculosis), and history of prior exposure to ATB or prior partially treated ATB (56, 57).

Because antigens within PPD are also found in other mycobacteria, the TST suffers from poor specificity in bacille Calmette-Guérin (BCG)-vaccinated persons (58). Moreover, the sensitivity of the TST used to diagnose LTBI may be reduced in patients on immunosuppressive therapy with a high rate of false-negative results (59). Since the early 2000s, in vitro blood tests measuring production of interferon (IFN)- γ by T cells exposed to antigens highly specific for *Mycobacterium tuberculosis* have been developed (60, 61). Extensive published literature suggests that T-cell INF- γ release assays (IGRAs) are a more specific and probably a more sensitive test for diagnosis of *M. tuberculosis* infection than the TST in immunocompetent persons (62), but available data in population affected by immune-mediated inflammatory diseases treated with conventional immunosuppressants are limited (level of evidence 2b) (63-65). Thus, IGRAs may be a promising tool for screening patients candidate to TNF blockade, but more data are required to validate their specific role in this setting.

Observational studies indicate that pre-treatment with antitubercular drugs in LTBI patients candidate to anti-TNF therapy may significantly reduce, even if not abolish, the risk of reactivation (level of evidence 2b) (56, 66). To date, no prospective controlled trial evaluating the optimal duration of prophylactic treatment and the optimal time frame between its beginning and starting of anti-TNF therapy has been published. Observational data suggest to start anti-tubercular drugs at least one month before starting biologic treatment (level of evidence 2b) (67) and to stop it after a period consistent with local guidelines.

Apart from data collected from a small series of patients (level of evidence 4) (68), no definitive data exist on the utility of repeating TST in previously negative patients during anti-TNF treatment. A history of TB after successful completion of a full course of anti-tuberculous treatment does not contraindicate the start (or re-start) of anti-TNF treatment (level of evidence 2b) (69)).

No data have been published on a significantly increased risk of tubercular

complication during treatment with rituximab, abatacept, and anakinra.

Recommendations

- LTBI screening (TST, chest x-ray and exposure history) is mandatory before starting a treatment with anti-TNF agents (grade of recommendation B).
- Until the real risk is well known, it is appropriate to screen for TB also patients considered for other biologic agents (rituximab and abatacept) according to local guidelines (grade of recommendation D).
- In selected patients (low-grade TST positivity and previous BCG vaccination) IGRAs may be useful to complete the screening program (grade of recommendation C).
- RA patients with a positive screening for LTBI must be treated with antitubercular drugs (*e.g.* isoniazid 300 mg/day for 9 months) for one month before starting biological treatment (grade of recommendation B).
- Re-screening should be considered only in areas of high TB prevalence (grade of recommendation C).

Other opportunistic infections

Data from RCTs with all biologic agents do not indicate an increased rate of opportunistic infections in treated patients as compared with control population (level of evidence 1b) (5, 14, 24, 33, 38, 41, 70, 71)). On the other hand, isolated cases of opportunistic infections have been reported in patients treated with anti-TNF with particular reference to macrophage/granuloma dependent infections such as listeriosis (72), coccidioidomycosis (73), and histoplasmosis (74, 75).

Recommendation

- Based on isolated reports, particular vigilance is needed for the possible development of opportunistic infections in RA patients treated with biological agents (grade of recommendation D).

Bacterial infections

Compared with the general population, patients with RA have an increased risk of infection, which is nearly twice as high as that observed in matched non-

RA controls (level of evidence 2b) (76, 77)).

In the main RCTs, the rates of infections in patients treated with anti-TNF have been similar to those reported in the placebo group (level of evidence 1b) (4-6, 13, 14, 24, 78, 79).

When considering serious infections separately, with the exception of etanercept RCTs (level of evidence 1b) (6, 24, 78, 80, 81), a trend toward an increased frequency compared to classical DMARDs has been noted regarding monoclonal anti-TNF antibodies (level of evidence 1b) (14, 70, 79), with a significant increase reported only in two studies with high (10 mg/kg) and low (3 mg/kg) dose infliximab (level of evidence 1b) (13, 82) and in one study with adalimumab (level of evidence 1b) (5). These findings are consistent with the results of a meta-analysis published in 2006, that included all RCTs performed with infliximab and adalimumab (level of evidence 1a) (83).

Post-marketing observational studies based on national registries produced conflicting results. Data from the German registry indicate that general and serious infections in patients treated with all TNF blockers are significantly increased as compared to DMARDs treated control group (level of evidence 2b) (84), whereas data from other large registries (level of evidence 2b) (85, 86) report a rate of infections similar to DMARDs treated RA population. The most common sites of infection were the respiratory tract (including pneumonia), skin and soft tissue, and the urinary tract.

RCTs data show a numerically but rarely significantly increased incidence of serious and non-serious bacterial infections associated with the use of abatacept (level of evidence 1b) (39, 87, 88), rituximab (level of evidence 1b) (33, 34), and anakinra (level of evidence 1b) (41, 42). Long-term data from registries and observational studies are needed to more clearly define the risk of serious infections when using biological agents other than anti-TNF.

Recommendation

- Patients on biological therapy should be carefully monitored for infectious complications. When a bacterial in-

fection is suspected, based on clinical judgement the biological agent should be stopped and the patient must be treated properly according to infection localisation and etiologic agent (grade of recommendation A).

Viral infections

The safety of TNF blockers in patients with human herpes virus (HHV) infections is a controversial issue. One study showed no infliximab-related reactivations of latent lymphotropic herpes viruses (cytomegalovirus, Epstein-Barr virus, or HHV-6) during 6 weeks of therapy (level of evidence 4) (89), whereas isolated case reports (level of evidence 4) have been published describing patients who developed HHV-8-related Kaposi's sarcoma (90), disseminated primary varicella infection (91), atypical varicella exanthema (92), and cytomegalovirus retinitis (93) during infliximab treatment. A recent observational study reported a significantly increased risk of varicella zoster virus (VZV) infections in RA patients treated with anti-TNF agents especially with monoclonal antibodies (level of evidence 2b) (94). The safety of TNF- α blockade in the presence of HIV infection is unknown at present. One case report indicated that TNF inhibitors may be associated with frequent polymicrobial infections, whereas several other reports suggest that these agents can be used safely and effectively in patients with HIV (level of evidence 4) (95-97).

Recommendations

- While HHV infections with EBV and CMV seem not to be associated with a particular risk during treatment with TNF- α antagonists, caution is required in adults suffering from VZV infection (grade of recommendation B).
- When VZV infection is suspected during biological treatment, therapy should be stopped and a specific antiviral treatment must be promptly started (grade of recommendation B).
- Screening for HIV before starting biological treatment should be performed only in patients with historical evidence of risk factors (grade of recommendation D).

Viral hepatitis

HBV-positive patients treated with TNF- α blocking agents have experienced raised liver function tests, increase of viral load and in some cases fatal hepatic failure (level of evidence 4) (98-102). No reactivation was reported in several observational studies during TNF- α inhibiting therapy in occult HBV carriers (HBc Ab positive - HBs Ag negative patients) (level of evidence 2b) (103). In HCV-infected RA patients, several short-term observational studies have shown no worsening or reactivation of viral disease associated with anti-TNF therapy (level of evidence 3b and 4) (102, 104-106). Moreover, in one reported controlled trial, the use of etanercept in association with standard anti-HCV therapy showed a significant improvement in viral load, liver enzymes, and symptoms (level of evidence 1b) (107). Hepatitis C and fatal hepatitis B reactivation have been reported in patients with non Hodgkin lymphoma (NHL) or other haematological diseases treated with rituximab (level of evidence 4) (108-112). On the other hand, there are several reports on the efficacy of rituximab in the treatment of HCV-related mixed cryoglobulinemia (level of evidence 3a and 4 (113-115)) and recent data have confirmed the safety of this treatment even in patients with concomitant severe liver disease (116). Prophylactic antiviral therapy with lamivudine seems to be useful to prevent hepatitis B reactivation in some patients treated with TNF blocking agents (level of evidence 4) (117-119) and in some descriptive studies in NHL patients treated with rituximab (level of evidence 4) (120, 121).

To date, there are no data about HCV/ HBV infections in patients treated with abatacept or anakinra.

Recommendations

- Hepatitis B and C screening tests must be performed before starting biologic treatments (grade of recommendation C).
- The use of anti-TNF- α drugs in active or non-active HCV infected patients seems to be safe and the prophylactic use of antiretroviral

agents is not mandatory. Since the long-term safety of TNF blocking agents and rituximab in this condition is unknown, careful monitoring of liver function tests and viral load is recommended (grade of recommendation D).

- TNF- α blocking agents and rituximab are contraindicated in HBV active carriers and should be used carefully in HBV inactive carriers in association with concomitant prophylactic antiviral therapy with lamivudine (grade of recommendation C).

Vaccinations

The ability of patients with RA to respond effectively to vaccination remains uncertain and it has been suggested that treatment with biologics may interfere with the effectiveness of vaccination in these patients.

The antibody response to pneumococcal (122-126), influenza (127-130), and measles-mumps-rubella (MMR) vaccine in patients treated with anti-TNF, especially in combination with methotrexate, is reported to be only modestly impaired, but the proportion of patients that achieves a protective titre is not significantly diminished by the use of TNF blocking therapies (level of evidence 3b and 4) (129, 131). Administration of the influenza vaccine on the day of infusion of infliximab seems to produce a better humoral response than vaccination 3 weeks later and may be thus preferable (level of evidence 3b) (132).

Rituximab reduces humoral responses following influenza and polysaccharide pneumococcal vaccination, but treatment with rituximab does not preclude administration of the vaccine (level of evidence 3b) (133, 134). Abatacept reduces the effectiveness of the immune response to tetanus or pneumococcal vaccine, but does not significantly inhibit the ability of healthy subjects to develop a clinically significant or positive immune response (level of evidence 2b) (135). There are no data on vaccination during treatment with anakinra.

Recommendations

- Influenza and pneumococcal vaccination, which can be indicated in RA, can also be safely recommended

for patients treated with anti-TNF, rituximab or abatacept (grade of recommendation B).

- In the absence of available data, the use of live attenuated vaccines (*e.g.* BCG, yellow fever, herpes zoster) is not recommended (grade of recommendation D).

Lymphomas and solid tumours

RA is a well-established risk factor for malignancies (especially lymphomas), but the role of biological and conventional DMARDs is still under debate.

A meta-analysis of main RCTs showed a three-fold increase of short-term (less than one year) occurrence of any malignancy with anti-TNF monoclonal antibodies (level of evidence 1a) (83), but not with etanercept (level of evidence 1b) (136). However, data from several large observational studies found no increase in the overall risk of any cancer related to anti-TNF therapy (level of evidence 2b and 3b) (137-139).

The risk of lymphoma is increased from two to five-fold in RA patients as compared to control population (140) and this increase appears to be related to disease activity and severity (141). So far, no individual clinical trial has reported an increased risk of developing lymphomas in patients exposed to TNF- α inhibitors, but none has been adequately powered to address this issue (level of evidence 1b) (5, 13, 25, 78, 142, 143). Data from observational studies are inconclusive (level of evidence 2b and 3b) (138, 139), but two large registries stated that TNF- α inhibitors seem to be not associated with an increased risk of developing lymphomas (level of evidence 2b (144, 145)).

The occurrence of solid malignancies with anti-TNF is not increased in RCTs (level of evidence 1b) and in long-term observational studies (level of evidence 2b) (137-139, 146), with the exception of an increased risk (OR: 1.5) (1.2-1.8) of non melanoma skin cancers (level of evidence 2b) (137, 146).

Data from RCTs showed no evidence that rituximab (level of evidence 1b) (33, 34), abatacept (level of evidence 1a) (40) and anakinra (level of evidence 1b) (41-43) are associated with an increased risk of any malignancy,

but data from long-term registries are needed to definitely settle this issue.

Recommendations

- In patients undergoing biological treatment for RA an accurate medical and family history should be taken to assess the risk of developing solid or haematopoietic malignancies (grade of recommendation C).
- Considering the timing of oncologic remission of 5 years, TNF inhibitors should be avoided in patients with a recent history of malignancy (<5 years) (grade of recommendation D).

Haematological disorders

Haematological dyscrasias such as aplastic anaemia, pancytopenia and neutropenia have been described in patients treated with TNF- α antagonists (level of evidence 4) (19, 147-152). These complications are extremely rare, and causality is very difficult, if not impossible, to ascertain.

No data on haematological dyscrasias during abatacept, anakinra, and rituximab treatment have been published.

Recommendation

If a patient develops any haematological dyscrasias while on anti-TNF therapy, the agent must be stopped and the patient should be evaluated for evidence of association with concomitant therapy or other underlying conditions (grade of recommendation C).

Cardiovascular manifestations

Two randomised controlled clinical trials (level of evidence 1b) conducted respectively with etanercept (153) and infliximab (154) in non-RA patients with advanced chronic heart failure (CHF, NYHA classes III and IV) failed to show a decrease in mortality and hospitalisations due to CHF with anti-TNF therapy. Moreover the ATTACH trial showed a trend towards a worse prognosis with high-dose infliximab in these patients (154). No increase in either CHF exacerbation or heart-failure related mortality was found among patients with RA and Crohn's disease receiving TNF blocking agents (level of evidence 2b) (155-157).

Several studies showed a decreased risk of cardiovascular events (transient ischaemic attack, stroke, or myocardial infarction) in patients treated with TNF blockers (level of evidence 2b) (158-160). No data on cardiovascular disorders during abatacept, anakinra, and rituximab treatment have been published.

Recommendations

- RA patients with no history of CHF and a concomitant indication for use of anti-TNF therapy do not need a baseline echocardiogram to screen for heart failure (grade of recommendation B).
- Patients with well-compensated, mild CHF (NYHA classes I and II) and a concomitant indication for use of anti-TNF therapy should have a baseline echocardiogram. Patients with a normal ejection fraction can receive therapy after a fully informed discussion with the patient and with close monitoring for any clinical signs or symptoms of worsening of heart failure. Anti-TNF therapy should be avoided in patients with a decreased ejection fraction (grade of recommendation B).
- In patients with NYHA classes III or IV heart failure, anti-TNF therapy is contraindicated (Grade of Recommendation B), as well as rituximab therapy in patients with NYHA class IV heart failure only (as indicated on product label).
- Patients who develop new-onset heart failure while on anti-TNF or rituximab therapy should have the therapy discontinued and should be evaluated for other causes of heart failure (grade of recommendation B).

Liver function tests

Mild elevations in liver function tests have been reported in one observational study with TNF-blockers in up to 17% of patients, but increases exceeding more than twice the upper normal limit have been reported only in 2.1% out of 6861 patients (level of evidence 2b) (161). Concomitant drugs and associated clinical conditions may confound the interpretation of these data.

No data of hepatic toxicity have been reported in RCTs with Rituximab (33, 34), Abatacept (37-39) and Anakinra (41, 43) (level of evidence 1b).

Recommendation

- Patients on biological treatment should be monitored for hepatic safety according to patient-related risk factors (grade of recommendation D).

New onset of psoriasis and other skin disorders

The incidence of immune-mediated skin lesion is increased in patients treated with anti-TNF agents (level of evidence 3b and 4) (162-164). The most frequent manifestations are exacerbation of pre-existing psoriatic lesions and new-onset psoriasis (vulgaris, pustulosa, and psoriatic palmoplantar pustolosis mainly) (level of evidence 4 (165-174)), with a risk apparently higher in adalimumab treated patients (level of evidence 2b) (175); granuloma annulare, Stevens-Johnson's syndrome, and skin vasculitis have also been reported (level of evidence 4) (163, 176, 177). In the majority of cases the local treatment of psoriatic lesions allowed to continue anti-TNF therapy without recrudescence of skin disease (level of evidence 4) (167, 168, 178, 179), although in more severe cases switching to another anti-TNF agent or withdrawal of the biologic treatment was necessary (level of evidence 4) (166, 180). Few cases of new-onset psoriasis during anakinra (181) and rituximab (182) therapy have also been reported (level of evidence 4). No data on skin toxicity during abatacept treatment have been published yet.

Recommendations

- When new-onset psoriasis occur during anti-TNF treatment, switch or withdrawal of biologic therapy is mandatory after failure of local management of skin lesions (grade of recommendation B).
- The persistence of skin lesions unresponsive to conventional local treatment is an indication to stop biologic therapy and to treat the skin disease with immunosuppressive agents. (grade of recommendation D).

Neurologic disorders

Case histories (level of evidence 4) report the possible association between anti-TNF-alpha treatment and demyelinating CNS lesions (183-187) and various disorders of peripheral nerve such as Guillain-Barré syndrome [188], Miller-Fisher syndrome (188), chronic inflammatory demyelinating polyneuropathy (189, 190), multifocal motor neuropathy with conduction block (191-193), mononeuropathy multiplex (194), and axonal sensorimotor polyneuropathies (195).

In the majority of cases, neurologic manifestations improve over a period of months after withdrawal of the TNF- α antagonist, with or without additional immuno-modulating treatment (level of evidence 4) (196). Some case-reports have been published on progressive multifocal leucoencephalopathy in SLE, RA and B-cell lymphoma patients treated with rituximab (level of evidence 4) (197, 198). No data on neurologic disorders during treatment with abatacept and anakinra have been published.

Recommendations

- Although anti-TNF related neurologic disorders are rare, anti-TNF therapy must be avoided in patients with a history of demyelinating disease (grade of recommendation D).
- Anti-TNF therapy must be immediately withdrawn when new neurologic signs and symptoms occur (grade of recommendation D).

Vasculitis

Although biological agents have successfully been used in isolated refractory cases of vasculitis, an increasing number of cases of vasculitis induced by biological agents (most of all anti-TNF, rarely rituximab or abatacept) have been described (level of evidence 4) (199-201). The clinical spectrum of vasculitic features was wide, but there was an overwhelming predominance of cutaneous involvement (in particular leukocytoclastic vasculitis) (202), renal involvement (203) and peripheral neuropathy (195). No data on vasculitides complicating anakinra and abatacept treatment have been published.

Recommendation

- In patients who develop this reaction, it is safer to stop the biologic therapy and treat with a regimen of steroids with or without immunosuppressive agents (grade of recommendation D).

Interstitial lung disease

The development of interstitial lung disease (ILD) in patients with rheumatic and autoimmune diseases treated with biologic therapies has been increasingly reported during last years (204-207); however there are no specific studies on the clinical presentation of this possible adverse event. In the vast majority of cases, ILD has been associated with anti TNF-alpha drugs, and two thirds of the ILD cases were treated with an association of methotrexate and biologic drugs. The incidence of ILD in biologic-treated RA patients varies from different studies and this may be due to a number of variables (ethnicity, underlying disease, type of study, drug availability in different countries, type of drug) (208, 209). However it seems that in RA patients treated with biologic agents the incidence of ILD is higher than in control patients (level of evidence 4). The main clinical features which may alert for a possible ILD are dyspnea, fever, cough. In these cases an exhaustive investigation is mandatory (lung function test, high-resolution pulmonary tomography, exclusion of an infectious disease) (level of evidence 2). Withdrawal of biologic therapy is recommended in these cases (level of evidence 4).

Recommendations

- When new-onset ILD occurs in patients treated with biologic agents, withdrawal of the drug should be recommended and an exhaustive investigation should be performed to exclude infectious disease (grade of recommendation D).
- In these patients, reinitiation of biologic treatment (especially with the same agent) is not recommended (grade of recommendation D).
- In patients with pre-existing ILD, anti-TNF agents should be avoided (grade of recommendation D).

Elective surgery

The occurrence of elective surgical interventions in rheumatic patients is a frequent condition (level of evidence 2b) (210). The real risk of complications in anti-TNF treated patients following surgical procedures remains unclear, but the peri-operative continuation of TNF blockers may cause surgical site infections and impaired wound healing (level of evidence 3b) (211-214). However, in the largest study focused on this item, peri-operative temporary discontinuation of biologic therapy has shown a trend toward a reduction in the risk of post-surgical complications (level of evidence 2b) (215). No data on the risk of surgical complications in patients receiving abatacept, rituximab, and anakinra have been published.

Recommendation

- In all patients with RA treated with biologic therapy undergoing elective surgery, the recommendation is to discontinue the treatment for a period of 2–4 times the half-life of the biologic agent according to the type of surgery (grade of recommendation C).

Pregnancy

Uncontrolled observations derived from case reports or registries found no increased foetal loss or miscarriages associated with the use of TNF blocking agents and suggest that conception and early pregnancy are not adversely affected by use of anti-TNF (pregnancy risk category B (216-225)). Uncommon adverse pregnancy outcomes observed with TNF inhibitor therapy appear to approximate those seen in women not receiving such therapy and may include premature birth, miscarriage, low birthweight, hypertension, and preeclampsia (level of evidence 4 (226-228)). A rare combination of congenital abnormalities (partial VATER defect – anal atresia and vertebral, tracheo-oesophageal, renal, cardiac and limb abnormalities) has been reported in association with etanercept therapy, but the causal relationship remains unclear (level of evidence 4 (229, 230)). Experience with rituximab in pregnant

women is too limited to allow any statement on safety in pregnancy, but when administered in the 2nd and 3rd trimester, B cell depletion can occur in the foetus (level of evidence 4 (231-233)). No data on exposure to abatacept and anakinra during human pregnancy have been published (pregnancy risk category C).

Recommendations

- Although it is difficult to prove with certainty, data suggest that women who inadvertently become pregnant while taking anti-TNF agents can be reassured that continuation of pregnancy does not appear to hold any increased risk to either themselves or their baby (grade of recommendation C).
- In the absence of formal studies, the regular use of anti-TNF therapies during pregnancy cannot be advocated and anti-TNF agents should be withdrawn when the patient becomes pregnant (grade of recommendation C).
- Because of the lack of definitive data and according to product label indications abatacept and rituximab should be discontinued 14 and 52 weeks respectively before a planned pregnancy (grade of recommendation D).

References

1. VALESINI G, MONTECUCCO C, CUTOLO M: Recommendations for the use of biologic (TNF-alpha blocking) agents in the treatment of rheumatoid arthritis in Italy. *Clin Exp Rheumatol* 2006; 24: 413-23.
2. CAPORALI R, PALLAVICINI FB, FILIPPINI M *et al.*: Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal. *Autoimmun Rev* 2009; 8: 274-80.
3. CHARLES PJ, SMEENK RJ, DE JONG J, FELDMANN M, MAINI RN: Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. *Arthritis Rheum* 2000; 43: 2383-90.
4. MAINI R, ST CLAIR EW, BREEDVELD F *et al.*: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. *Lancet* 1999; 354: 1932-9.
5. KEYSTONE EC, KAVANAUGH AF, SHARP JT

- et al.*: Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. *Arthritis Rheum* 2004; 50: 1400-11.
6. WEINBLATT ME, KREMER JM, BANKHURST AD *et al.*: A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. *N Engl J Med* 1999; 340: 253-9.
7. DE RYCKE L, KRUIHOF E, VAN DAMME N *et al.*: Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. *Arthritis Rheum* 2003; 48: 1015-23.
8. FERRARO-PEYRET C, COURY F, TEBIB JG, BIENVENU J, FABIEN N: Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study. *Arthritis Res Ther* 2004; 6: R535-43.
9. JONSDOTTIR T, FORSLID J, HARJU A *et al.*: Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies. *Ann Rheum Dis* 2004; 63: 1075-8.
10. ATZENI F, DORIA A, GHIRARDELLO A *et al.*: Organ-specific autoantibodies in patients with rheumatoid arthritis treated with adalimumab: a prospective long-term follow-up. *Autoimmunity* 2008; 41: 87-91.
11. GONNET-GRACIA C, BARNETCHE T, RICHEZ C *et al.*: Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers. *Clin Exp Rheumatol* 2008; 26: 401-
12. BOBBIO-PALLAVICINI F, ALPINI C, CAPORALI R, AVALLE S, BUGATTI S, MONTECUCCO C: Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. *Arthritis Res Ther* 2004; 6: R264-72.
13. ST CLAIR EW, VAN DER HEIJDE D, SMOLEN JS *et al.*: Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. *Arthritis Rheum* 2004; 50: 3432-43.
14. WEINBLATT ME, KEYSTONE EC, FURST DE *et al.*: Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. *Arthritis Rheum* 2003; 48: 35-45.
15. FAVALLI EG, SINIGAGLIA L, VARENNA M, ARNOLDI C: Drug-induced lupus following treatment with infliximab in rheumatoid arthritis. *Lupus* 2002; 11: 753-5.
16. SHAKOOR N, MICHALSKA M, HARRIS CA, BLOCK JA: Drug-induced systemic lupus erythematosus associated with etanercept therapy. *Lancet* 2002; 359: 579-80.
17. DE BANDT M, SIBILIA J, LE LOËT X *et al.*: Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy:

- a French national survey. *Arthritis Res Ther* 2005; 7: R545-51.
18. RAMOS-CASALS M, BRITO-ZERÓN P, MUÑOZ S *et al.*: Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. *Medicine* (Baltimore) 2007; 86: 242-51.
 19. FAVALLI EG, VARENNA M, SINIGAGLIA L: Drug-induced agranulocytosis during treatment with infliximab in enteropathic spondyloarthritis. *Clin Exp Rheumatol* 2005; 23: 247-50.
 20. COSTA MF, SAID NR, ZIMMERMANN B: Drug-induced lupus due to anti-tumor necrosis factor alpha agents. *Semin Arthritis Rheum* 2008; 37: 381-7.
 21. BACQUET-DESCHRYVER H, JOUEN F, QUILLARD M *et al.*: Impact of three anti-TNF-alpha biologics on existing and emergent autoimmunity in rheumatoid arthritis and spondylarthropathy patients. *J Clin Immunol* 2008; 28: 445-55.
 22. ABUNASSER J, FOROUHAR FA, METERSKY ML: Etanercept-induced lupus erythematosus presenting as a unilateral pleural effusion. *Chest* 2008; 134: 850-3.
 23. BUCHLER M, VITAL EM, EMERY P: Abatacept in the treatment of rheumatoid arthritis. *Arthritis Res Ther* 2008; 10 (Suppl. 1): S5.
 24. KLARESKOG L, VAN DER HEIJDE D, DE JAGER JP *et al.*: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. *Lancet* 2004; 363: 675-81.
 25. MAINI RN, BREEDVELD FC, KALDEN JR *et al.*: Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. *Arthritis Rheum* 2004; 50: 1051-65.
 26. GAMARRA RM, MCGRAW SD, DRELICHMAN VS, MAAS LC: Serum sickness-like reactions in patients receiving intravenous infliximab. *J Emerg Med* 2006; 30: 41-4.
 27. SANDBORN WJ: Optimizing anti-tumor necrosis factor strategies in inflammatory bowel disease. *Curr Gastroenterol Rep* 2003; 5: 501-5.
 28. AUGUSTSSON J, EKSBERG S, ERNESTAM S, GULLSTRÖM E, VAN VOLLENHOVEN R: Low-dose glucocorticoid therapy decreases risk for treatment-limiting infusion reaction to infliximab in patients with rheumatoid arthritis. *Ann Rheum Dis* 2007; 66: 1462-6.
 29. FARRELL RJ, ALSAHLI M, JEEN Y-T *et al.*: Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. *Gastroenterology* 2003; 124: 917-24.
 30. SANY J, KAISER MJ, JORGENSEN C, TRAPE G: Study of the tolerance of infliximab infusions with or without betamethasone premedication in patients with active rheumatoid arthritis. *Ann Rheum Dis* 2005; 64: 1647-9.
 31. BUCHLER M, BRYER DJ, LINDSAY S *et al.*: Shortening infusion times for infliximab administration. *Rheumatology* 2006; 45: 485-6.
 32. LEQUERRÉ T, VITTECOQ O, KLEMMER N *et al.*: Management of infusion reactions to infliximab in patients with rheumatoid arthritis or spondyloarthritis: experience from an immunotherapy unit of rheumatology. *J Rheumatol* 2006; 33: 1307-14.
 33. EMERY P, FLEISCHMANN R, FILIPOWICZ-SOSNOWSKA *et al.*: The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. *Arthritis Rheum* 2006; 54: 1390-400.
 34. COHEN SB, EMERY P, GREENWALD MW *et al.*: Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. *Arthritis Rheum* 2006; 54: 2793-806.
 35. TODD DJ, HELFGOTT SM: Serum sickness following treatment with rituximab. *J Rheumatol* 2007; 34: 430-3.
 36. FLEISCHMANN RM: Safety of biologic therapy in rheumatoid arthritis and other autoimmune diseases: focus on rituximab. *Semin Arthritis Rheum* 2009; 38: 265-80.
 37. KREMER JM, GENANT HK, MORELAND LW *et al.*: Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. *Ann Intern Med* 2006; 144: 865-76.
 38. GENOVESE MC, BECKER J-C, SCHIFF MH *et al.*: Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. *N Engl J Med* 2005; 353: 1114-23.
 39. SCHIFF M, PRITCHARD C, HUFFSTUTTER JE *et al.*: The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumor necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. *Ann Rheum Dis* 2009; 68: 1708-14.
 40. SIBILIA J, WESTHOVENS R: Safety of T-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis. *Clin Exp Rheumatol* 2007; 25 (Suppl. 46): S46-56.
 41. FLEISCHMANN RM, SCHECHTMAN J, BENNETT R *et al.*: Anakinra, a recombinant human interleukin-1 receptor antagonist (r-mHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial. *Arthritis Rheum* 2003; 48: 927-34.
 42. COHEN SB, HURD E, CUSH J *et al.*: Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. *Arthritis Rheum* 2002; 46: 614-24.
 43. FLEISCHMANN RM, TESSER J, SCHIFF MH *et al.*: Safety of extended treatment with anakinra in patients with rheumatoid arthritis. *Ann Rheum Dis* 2006; 65: 1006-12.
 44. FLYNN JL, GOLDSTEIN MM, CHAN J *et al.*: Tumor necrosis factor-alpha is required in the protective immune response against *Mycobacterium tuberculosis* in mice. *Immunity* 1995; 2: 561-72.
 45. ROACH DR, BEAN AGD, DEMANGEL C *et al.*: TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. *J Immunol* 2002; 168: 4620-7.
 46. MOHAN VP, SCANGA CA, YU K *et al.*: Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. *Infect Immun* 2001; 69: 1847-55.
 47. NÚÑEZ MARTÍNEZ O, RIPOLL NOISEUX C, CARNEROS MARTÍN JA, GONZÁLEZ LARA V, GREGORIO MARAÑÓN HG: Reactivation tuberculosis in a patient with anti-TNF-alpha treatment. *Am J Gastroenterol* 2001; 96: 1665-6.
 48. KEANE J, GERSHON S, WISE RP *et al.*: Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. *N Engl J Med* 2001; 345: 1098-104.
 49. DURSUN AB, KALAÇ N, OZKAN B, YILMAZ F: Pulmonary tuberculosis in patients with rheumatoid arthritis (four case reports). *Rheumatol Int* 2002; 21: 153-7.
 50. GOMEZ-REINO JJ, CARMONA L, VALVERDE VR *et al.*: Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. *Arthritis Rheum* 2003; 48: 2122-7.
 51. WALLIS RS, BRODER MS, WONG JY, HANSON ME, BEENHOUWER DO: Granulomatous infectious diseases associated with tumor necrosis factor antagonists. *Clin Infect Dis* 2004; 38: 1261-5.
 52. SALIU OY, SOFER C, STEIN DS, SCHWANDER SK, WALLIS RS: Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity. *J Infect Dis* 2006; 194: 486-92.
 53. TUBACH F, SALMON D, RAVAUD P *et al.*: Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. *Arthritis Rheum* 2009; 60: 1884-94.
 54. DIXON WG, HYRICH KL, WATSON KD *et al.*: Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). *Ann Rheum Dis* 2010; 69: 522-8.
 55. WINTHROP KL, CHANG E, YAMASHITA S, IADEMARCO MF, LOBUE PA: Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy. *Emerg Infect Dis* 2009; 15: 1556-61.
 56. GOMEZ-REINO JJ, CARMONA L, ANGEL DESCALZO M, GROUP B: Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. *Arthritis Rheum* 2007; 57: 756-61.
 57. WINTHROP KL: Update on tuberculosis and other opportunistic infections associated with drugs blocking tumour necrosis factor {alpha}. *Ann Rheum Dis* 2005; 64 (Suppl. 4): iv29-30.
 58. HUEBNER RE, SCHEIN MF, BASS JB: The tu-

- berculin skin test. *Clin Infect Dis* 1993; 17: 968-75.
59. JASMER RM, NAHID P, HOPEWELL PC: Clinical practice. Latent tuberculosis infection. *N Engl J Med* 2002; 347: 1860-6.
 60. MORI T, SAKATANI M, YAMAGISHI F *et al.*: Specific detection of tuberculosis infection: an interferon-gamma-based assay using new antigens. *Am J Respir Crit Care Med* 2004; 170: 59-64.
 61. LALVANI A: Diagnosing tuberculosis infection in the 21st century: new tools to tackle an old enemy. *Chest* 2007; 131: 1898-906.
 62. PAI M, RILEY LW, COLFORD JM: Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. *Lancet Infect Dis* 2004; 4: 761-76.
 63. LALVANI A, MILLINGTON KA: Screening for tuberculosis infection prior to initiation of anti-TNF therapy. *Autoimmunity Reviews* 2008; 8: 147-52.
 64. MURAKAMI S, TAKENO M, KIRINO Y *et al.*: Screening of tuberculosis by interferon-gamma assay before biologic therapy for rheumatoid arthritis. *Tuberculosis* (Edinb) 2009; 89: 136-41.
 65. BEHAR SM, SHIN DS, MAIER A *et al.*: Use of the T-SPOT.TB assay to detect latent tuberculosis infection among rheumatic disease patients on immunosuppressive therapy. *J Rheumatol* 2009; 36: 546-51.
 66. LAFFITTE E, JANSSENS JP, ROUX-LOMBARD P *et al.*: Tuberculosis screening in patients with psoriasis before antitumour necrosis factor therapy: comparison of an interferon-gamma release assay vs. tuberculin skin test. *Br J Dermatol* 2009; 161: 797-800.
 67. CARMONA L, GÓMEZ-REINO JJ, RODRÍGUEZ-VALVERDE V *et al.*: Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. *Arthritis Rheum* 2005; 52: 1766-72.
 68. FUCHS I, AVNON L, FREUD T, ABU-SHAKRA M: Repeated tuberculin skin testing following therapy with TNF-alpha inhibitors. *Clin Rheumatol* 2009; 28: 167-72.
 69. DENIS B, LEFORT A, FLIPO RM *et al.*: Long-term follow-up of patients with tuberculosis as a complication of tumour necrosis factor (TNF)-alpha antagonist therapy: safe reinitiation of TNF-alpha blockers after appropriate anti-tuberculous treatment. *Clin Microbiol Infect* 2008; 14: 183-6.
 70. LIPSKY PE, VAN DER HEIJDE DM, ST CLAIR EW *et al.*: Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. *N Engl J Med* 2000; 343: 1594-602.
 71. WEINBLATT ME, COMBE B, COVUCCI A *et al.*: Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study. *Arthritis Rheum* 2006; 54: 2807-16.
 72. SLIFMAN NR, GERSHON SK, LEE J-H, EDWARDS ET, BRAUN MM: Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. *Arthritis Rheum* 2003; 48: 319-24.
 73. BERGSTROM L, YOCUM DE, AMPEL NM *et al.*: Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists. *Arthritis Rheum* 2004; 50: 1959-66.
 74. LEE J-H, SLIFMAN NR, GERSHON SK *et al.*: Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. *Arthritis Rheum* 2002; 46: 2565-70.
 75. JAIN VV, EVANS T, PETERSON MW: Reactivation histoplasmosis after treatment with anti-tumor necrosis factor alpha in a patient from a nonendemic area. *Respir Med* 2006; 100: 1291-3.
 76. CAPORALI R, CAPRIOLI M, BOBBIO-PALLAVICINI F, MONTECUCCO C: DMARDS and infections in rheumatoid arthritis. *Autoimmun Rev*. 2008 Dec; 8: 139-43.
 77. DORAN MF, CROWSON CS, POND GR, O'FALLON WM, GABRIEL SE: Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. *Arthritis Rheum* 2002; 46: 2287-93.
 78. EMERY P, BREEDVELD FC, HALL S *et al.*: Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomized, double-blind, parallel treatment trial. *Lancet* 2008; 372: 375-82.
 79. BREEDVELD FC, WEISMAN MH, KAVANAUGH AF *et al.*: The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. *Arthritis Rheum* 2006; 54: 26-37.
 80. MORELAND LW, SCHIFF MH, BAUMGARTNER SW *et al.*: Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. *Ann Intern Med* 1999; 130: 478-86.
 81. GENOVESE MC, BATHON JM, MARTIN RW *et al.*: Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. *Arthritis Rheum* 2002; 46: 1443-50.
 82. WESTHOVENS R, YOCUM D, HAN J *et al.*: The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. *Arthritis Rheum* 2006; 54: 1075-86.
 83. BONGARTZ T, SUTTON AJ, SWEETING MJ *et al.*: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. *JAMA* 2006; 295: 2275-85.
 84. LISTING J, STRANGFELD A, KARY S *et al.*: Infections in patients with rheumatoid arthritis treated with biologic agents. *Arthritis Rheum* 2005; 52: 3403-12.
 85. DIXON WG, WATSON KD, LUNT M *et al.*: Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. *Arthritis Rheum* 2006; 54: 2368-76.
 86. FAVALLI EG, DESIATI F, ATZENI F *et al.*: Serious infections during anti-TNF-alpha treatment in rheumatoid arthritis patients. *Autoimmun Rev* 2009; 8: 266-73.
 87. WESTHOVENS R, ROBLES M, XIMENES AC *et al.*: Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. *Ann Rheum Dis* 2009; 68: 1870-7.
 88. GENOVESE MC, SCHIFF MH, LUGGEN M *et al.*: Efficacy and safety of the selective costimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. *Ann Rheum Dis* 2008; 67: 547-54.
 89. TORRE-CISNEROS J, DEL CASTILLO M, CASTÓN JJ *et al.*: Infliximab does not activate replication of lymphotropic herpesviruses in patients with refractory rheumatoid arthritis. *Rheumatology* 2005; 44: 1132-5.
 90. COHEN CD, HORSTER S, SANDER CA, BOGNER JR: Kaposi's sarcoma associated with tumour necrosis factor alpha neutralising therapy. *Ann Rheum Dis* 2003; 62: 684.
 91. VONKEMAN H, TEN NAPEL C, RASKER H, VAN DE LAAR M: Disseminated primary varicella infection during infliximab treatment. *J Rheumatol* 2004; 31: 2517-8.
 92. CHOI H-J, KIM M-Y, KIM HO, PARK YM: An atypical varicella exanthem associated with the use of infliximab. *Int J Dermatol* 2006; 45: 999-1000.
 93. HAERTER G, MANFRAS BJ, DE JONG-HESSE Y *et al.*: Cytomegalovirus retinitis in a patient treated with anti-tumor necrosis factor alpha antibody therapy for rheumatoid arthritis. *Clin Infect Dis* 2004; 39: e88-94.
 94. STRANGFELDA, LISTING J, HERZER P *et al.*: Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. *JAMA* 2009; 301: 737-44.
 95. KAUR PP, CHAN VC, BERNEY SN: Successful etanercept use in an HIV-positive patient with rheumatoid arthritis. *J Clin Rheumatol* 2007; 13: 79-80.
 96. SELLAM J, BOUVARD B, MASSON C *et al.*: Use of infliximab to treat psoriatic arthritis in HIV-positive patients. *Joint Bone Spine* 2007; 74: 197-200.
 97. CEPEDA EJ, WILLIAMS FM, ISHIMORI ML, WEISMAN MH, REVELLE JD: The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. *Ann Rheum Dis* 2008; 67: 710-2.
 98. CALABRESE LH, ZEIN N, VASSILOPOULOS D: Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. *Ann Rheum Dis* 2004; 63 (Suppl. 2): ii18-ii24.
 99. ROUX CH, BROCCO Q, BREUIL V, ALBERT C, EULLER-ZIEGLER L: Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. *Rheumatology* 2006; 45: 1294-7.

100. ESTEVE M, LORAS C, GONZÁLEZ-HUIX F: Lamivudine resistance and exacerbation of hepatitis B in infliximab-treated Crohn's disease patient. *Inflamm Bowel Dis* 2007; 13: 1450-1.
101. MONTIEL PM, SOLIS JA, CHIRINOS JA *et al.*: Hepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient. *Liver Int* 2008; 28: 718-20.
102. LI S, KAUR PP, CHAN V, BERNEY S: Use of tumor necrosis factor-alpha (TNF-alpha) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients. *Clin Rheumatol* 2009; 28: 787-91.
103. CAPORALI R, BOBBIO-PALLAVICINI F, ATZENI F *et al.*: Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases. *Arthritis Care Res (Hoboken)*. 2010; 62: 749-54.
104. PETERSON JR, HSU FC, SIMKIN PA, WENER MH: Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. *Ann Rheum Dis* 2003; 62: 1078-82.
105. DE SIMONE C, PARADISI A, CAPIZZI R *et al.*: Etanercept therapy in two patients with psoriasis and concomitant hepatitis C. *J Am Acad Dermatol* 2006; 54: 1102-4.
106. FERRI C, FERRACCIOLI G, FERRARI D *et al.*: Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. *J Rheumatol* 2008; 35: 1944-9.
107. ZEIN NN, GROUP ES: Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. *J Hepatol* 2005; 42: 315-22.
108. KHALED Y, HANBALI A: Hepatitis B virus reactivation in a case of Waldenström's macroglobulinemia treated with chemotherapy and rituximab despite adefovir prophylaxis. *Am J Hematol*. 2007; 82: 688.
109. ENNISHI D, TERUI Y, YOKOYAMA M *et al.*: Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV-infected CD20-positive B-cell lymphoma undergoing rituximab combination chemotherapy. *Am J Hematol* 2008; 83: 59-62.
110. GARCIA-RODRIGUEZ MJ, CANALES MA, HERNANDEZ-MARAVAR D, HERNANDEZ-NAVARRO F: Late reactivation of resolved hepatitis B virus infection: an increasing complication post rituximab-based regimens treatment? *Am J Hematol* 2008; 83: 673-5.
111. RODRÍGUEZ-ESCALERA C, FERNÁNDEZ-NEBRO A: The use of rituximab to treat a patient with ankylosing spondylitis and hepatitis B. *Rheumatology* 2008; 47: 1732-3.
112. HANBALI A, KHALED Y: Incidence of hepatitis B reactivation following Rituximab therapy. *Am J Hematol* 2009; 84: 195.
113. RAMOS-CASALS M, BRITO-ZERÓN P, MUÑOZ S, SOTO M-J, GROUP BS: A systematic review of the off-label use of biological therapies in systemic autoimmune diseases. *Medicine (Baltimore)* 2008; 87: 345-64.
114. DE VITA S, QUARTUCCIO L, FABRIS M: Rituximab in mixed cryoglobulinemia: increased experience and perspectives. *Dig Liver Dis* 2007; 39 (Suppl. 1): S122-8.
115. ROCCATELLO D, BALDOVINO S, ROSSI D *et al.*: Rituximab as a therapeutic tool in severe mixed cryoglobulinemia. *Clin Rev Allergy Immunol* 2008; 34: 111-7.
116. PETRARCA A, RIGACCI L, CAINI P *et al.*: Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease. *Blood* 2010; 116: 335-42.
117. MARZANO A, ANGELUCCI E, ANDREONE P *et al.*: Prophylaxis and treatment of hepatitis B in immunocompromised patients. *Dig Liver Dis* 2007; 39: 397-408.
118. BENUCCI M, MANFREDI M, MECOCCHI L: Effect of etanercept plus lamivudine in a patient with rheumatoid arthritis and viral hepatitis B. *J Clin Rheumatol* 2008; 14: 245-6.
119. ZINGARELLI S, AIRÒ P, FRASSI M *et al.*: Prophylaxis and therapy of HBV infection in 20 patients treated with disease modifying antirheumatic drugs or with biological agents for rheumatic diseases. *Reumatismo* 2008; 60: 22-7.
120. HE Y-F, LI Y-H, WANG F-H *et al.*: The effectiveness of lamivudine in preventing hepatitis B viral reactivation in rituximab-containing regimen for lymphoma. *Ann Hematol* 2008; 87: 481-5.
121. TAKAHASHI T, KOIKE T, HASHIMOTO S *et al.*: A case of lamivudine-sensitive de novo acute hepatitis B induced by rituximab with the CHOP regimen for diffuse large B cell lymphoma. *Hepatology international* 2009; 3: 316-22.
122. KAPETANOVIC MC, SAXNE T, SJÖHOLM A *et al.*: Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. *Rheumatology* 2006; 45: 106-11.
123. ELKAYAM O, CASPI D, REITBLATT T, CHARBONEAU D, RUBINS JB: The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. *Semin Arthritis Rheum* 2004; 33: 283-8.
124. MEASE PJ, RITCHLIN CT, MARTIN RW *et al.*: Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept. *J Rheumatol* 2004; 31: 1356-61.
125. WRIGHT SA, TAGGART AJ: Pneumococcal vaccination for RA patients on TNF-alpha antagonists. *Rheumatology* 2004; 43: 523.
126. VISVANATHAN S, KEENAN GF, BAKER DG, LEVINSON AI, WAGNER CL: Response to pneumococcal vaccine in patients with early rheumatoid arthritis receiving infliximab plus methotrexate or methotrexate alone. *J Rheumatol* 2007; 34: 952-7.
127. KAINE JL, KIVITZ AJ, BIRBARA C, LUO AY: Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. *J Rheumatol* 2007; 34: 272-9.
128. KAPETANOVIC MC, SAXNE T, NILSSON J-A, GEBOREK P: Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients. *Rheumatology* 2007; 46: 608-11.
129. GELINCK LBS, VAN DER BIJL AE, BEYER WEP *et al.*: The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination. *Ann Rheum Dis* 2008; 67: 713-6.
130. FOMIN I, CASPI D, LEVY V *et al.*: Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers. *Ann Rheum Dis* 2006; 65: 191-4.
131. BORTE S, LIEBERT UG, BORTE M, SACK U: Efficacy of measles, mumps and rubella revaccination in children with juvenile idiopathic arthritis treated with methotrexate and etanercept. *Rheumatology* 2009; 48: 144-8.
132. ELKAYAM O, BASHKIN A, MANDELBOIM M *et al.*: The Effect of Infliximab and Timing of Vaccination on the Humoral Response to Influenza Vaccination in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis. *Semin Arthritis Rheum* 2009.
133. GELINCK LBS, TENG YKO, RIMMELZWAAN GF *et al.*: Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with rituximab. *Ann Rheum Dis* 2007; 66: 1402-3.
134. OREN S, MANDELBOIM M, BRAUN-MOSCOVICI Y *et al.*: Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response. *Ann Rheum Dis* 2008; 67: 937-41.
135. TAY L, LEON F, VRATSANOS G, RAYMOND R, CORBO M: Vaccination response to tetanus toxoid and 23-valent pneumococcal vaccines following administration of a single dose of abatacept: a randomized, open-label, parallel group study in healthy subjects. *Arthritis Res Ther* 2007; 9: R38.
136. BONGARTZ T, WARREN FC, MINES D *et al.*: Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. *Ann Rheum Dis* 2009; 68: 1177-83.
137. WOLFE F, MICHAUD K: Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. *Arthritis Rheum* 2007; 56: 2886-95.
138. GEBOREK P, BLADSTRÖM A, TURESSON C *et al.*: Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. *Ann Rheum Dis* 2005; 64: 699-703.
139. SETOGUCHI S, SOLOMON DH, WEINBLATT ME *et al.*: Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. *Arthritis Rheum* 2006; 54: 2757-64.
140. FRANKLIN J, LUNT M, BUNN D, SYMMONS D, SILMAN A: Incidence of lymphoma in a large primary care derived cohort of cases of inflammatory polyarthritis. *Ann Rheum Dis* 2006; 65: 617-22.
141. BAECKLUND E, ILIADOU A, ASKLING J *et al.*: Association of chronic inflammation,

- not its treatment, with increased lymphoma risk in rheumatoid arthritis. *Arthritis Rheum* 2006; 54: 692-701.
142. WEINBLATT ME, KEYSTONE EC, FURST DE *et al.*: Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. *Ann Rheum Dis* 2006; 65: 753-9.
 143. VAN DER HEIJDE D, KLARESKOG L, RODRIGUEZ-VALVERDE V *et al.*: Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. *Arthritis Rheum* 2006; 54: 1063-74.
 144. ASKLING J, BAECKLUND E, GRANATH F *et al.*: Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. *Ann Rheum Dis* 2009; 68: 648-53.
 145. WOLFE F, MICHAUD K: The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. *Arthritis Rheum* 2007; 56: 1433-9.
 146. ASKLING J, FORED CM, BRANDT L *et al.*: Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. *Ann Rheum Dis* 2005; 64: 1421-6.
 147. KURUVILLA J, LEITCH HA, VICKARS LM *et al.*: Aplastic anemia following administration of a tumor necrosis factor-alpha inhibitor. *Eur J Haematol* 2003; 71: 396-8.
 148. MARCHESONI A, ARREGHINI M, PANNI B, BATTAFARANO N, UZIEL L: Life-threatening reversible bone marrow toxicity in a rheumatoid arthritis patient switched from leflunomide to infliximab. *Rheumatology* 2003; 42: 193-4.
 149. VIDAL F, FONTOVA R, RICHART C: Severe neutropenia and thrombocytopenia associated with infliximab. *Ann Intern Med* 2003; 139: W-W63.
 150. THEODORIDOU A, KARTSIOS C, YIANNAKI E, MARKALA D, SETTAS L: Reversible T-large granular lymphocyte expansion and neutropenia associated with adalimumab therapy. *Rheumatol Int* 2006; 27: 201-2.
 151. MONTANÉ E, SALLÉS M, BARRIOCANAL A *et al.*: Antitumor necrosis factor-induced neutropenia: a case report with double positive rechallenges. *Clin Rheumatol* 2007; 26: 1527-9.
 152. OTTAVIANIS, CERF-PAYRASTREI, KEMICHE F, PERTUISSET E: Adalimumab-induced neutropenia in a patient with rheumatoid arthritis. *Joint Bone Spine* 2009; 76: 312-3.
 153. MANN DL, McMURRAY JVV, PACKER M *et al.*: Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). *Circulation* 2004; 109: 1594-602.
 154. CHUNG ES, PACKER M, LO KH *et al.*: Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. *Circulation* 2003; 107: 3133-40.
 155. WOLFE F, MICHAUD K: Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. *Am J Med* 2004; 116: 305-11.
 156. COLE J, BUSTI A, KAZI S: The incidence of new onset congestive heart failure and heart failure exacerbation in Veteran's Affairs patients receiving tumor necrosis factor alpha antagonists. *Rheumatol Int* 2007; 27: 369-73.
 157. CURTIS JR, KRAMER JM, MARTIN C *et al.*: Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNF-alpha antagonists. *Rheumatology (Oxford)* 2007; 46: 1688-93.
 158. JACOBSSON LTH, TURESSON C, GÜLFE A *et al.*: Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. *J Rheumatol* 2005; 32: 1213-8.
 159. DIXON WG, WATSON KD, LUNT M *et al.*: Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. *Arthritis Rheum* 2007; 56: 2905-12.
 160. LISTING J, STRANGFELD A, KEKOW J *et al.*: Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis? *Arthritis Rheum* 2008; 58: 667-77.
 161. SOKOLOVE J, STRAND V, GREENBERG JD *et al.*: Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. *Ann Rheum Dis* 2010; 69: 1612-7.
 162. LEE H-H, SONG I-H, FRIEDRICH M *et al.*: Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. *Br J Dermatol* 2007; 156: 486-91.
 163. DAVAINÉ AC, SARAUX A, PRIGENT S *et al.*: Cutaneous events during treatment of chronic inflammatory joint disorders with anti-tumour necrosis factor alpha: a cross-sectional study. *J Eur Acad Dermatol Venereol* 2008; 22: 1471-7.
 164. EXARCHOU S, VOULGARIS P, MARKATSELI T, ZIOGA A, DROSOS A: Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors. *Scand J Rehabil Med* 2009; 1-4.
 165. DEREURE O, GUILLOT B, JORGENSEN C *et al.*: Psoriatic lesions induced by antitumour necrosis factor-alpha treatment: two cases. *Br J Dermatol* 2004; 151: 506-7.
 166. MICHAËLSSON G, KAJERMO U, MICHAËLSSON A, HAGFORSÉN E: Infliximab can precipitate as well as worsen palmoplantar pustulosis: possible linkage to the expression of tumour necrosis factor-alpha in the normal palmar eccrine sweat duct? *Br J Dermatol* 2005; 153: 1243-4.
 167. SFIKAKIS PP, ILIOPOULOS A, ELEZOGLUO A, KITTAS C, STRATIGOS A: Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. *Arthritis Rheum* 2005; 52: 2513-8.
 168. STARMANS-KOOL MJF, PEETERS HRM, HOUBEN HHML: Pustular skin lesions in patients treated with infliximab: report of two cases. *Rheumatol Int* 2005; 25: 550-2.
 169. GONCALVES DP, LAURINDO I, SCHEINBERG MA: The appearance of pustular psoriasis during antitumor necrosis factor therapy. *J Clin Rheumatol* 2006; 12: 262.
 170. MATTHEWS C, ROGERS S, FITZGERALD O: Development of new-onset psoriasis while on anti-TNFalpha treatment. *Ann Rheum Dis* 2006; 65: 1529-30.
 171. ROUX CH, BROCCO O, LECCIA N *et al.*: New-onset psoriatic palmoplantar pustulosis following infliximab therapy: a class effect? *J Rheumatol* 2007; 34: 434-7.
 172. BORRÁS-BLASCO J, GRACIA-PÉREZ A, NUÑEZ-CORNEJO C *et al.*: Exacerbation of psoriatic skin lesions in a patient with psoriatic arthritis receiving adalimumab. *J Clin Pharm Ther* 2008; 33: 321-5.
 173. CUCHACOVICH R, ESPINOZA CG, VIRK Z, ESPINOZA LR: Biologic therapy (TNF-alpha antagonists)-induced psoriasis: a cytokine imbalance between TNF-alpha and IFN-alpha? *J Clin Rheumatol* 2008; 14: 353-6.
 174. RALLIS E, KORFITIS C, STAVROPOULOU E, PAPACONSTANTIS M: Onset of palmoplantar pustular psoriasis while on adalimumab for psoriatic arthritis: A 'class effect' of TNF-alpha antagonists or simply an anti-psoriatic treatment adverse reaction? *J Dermatolog Treat* 2009; 1-3.
 175. HARRISON MJ, DIXON WG, WATSON KD *et al.*: Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. *Ann Rheum Dis* 2009; 68: 209-15.
 176. DUBOSC AE, PERROUD A-M, BAGOT M *et al.*: Cutaneous granulomas during infliximab therapy for spondyloarthritis. *J Rheumatol* 2008; 35: 1222-3.
 177. HU S, COHEN D, MURPHY G, MODY E, QURESHI AA: Interstitial granulomatous dermatitis in a patient with rheumatoid arthritis on etanercept. *Cutis* 2008; 81: 336-8.
 178. KARY S, WORM M, AUDRING H *et al.*: New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists. *Ann Rheum Dis* 2006; 65: 405-7.
 179. COHEN JD, BOURNERIAS I, BUFFARD V *et al.*: Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series. *J Rheumatol* 2007; 34: 380-5.
 180. GOIRIZ R, DAUDÉN E, PÉREZ-GALAS, GUHL G, GARCÍA-DÍEZA A: Flare and change of psoriasis morphology during the course of treatment with tumour necrosis factor blockers. *Clin Exp Dermatol* 2007; 32: 176-9.
 181. GONZÁLEZ-LÓPEZ MA, MARTÍNEZ-TABOADA VM, GONZÁLEZ-VELA MC, FERNÁNDEZ-LLACA H, VAL-BERNAL JF: New-onset psoriasis following treatment with the interleukin-1 receptor antagonist anakinra. *Br J Dermatol* 2008; 158: 1146-8.

182. MIELKE F, SCHNEIDER-OBBERMEYER J, DÖRNER T: Onset of psoriasis with psoriatic arthropathy during rituximab treatment of non-Hodgkin lymphoma. *Ann Rheum Dis* 2008; 67: 1056-7.
183. MOHAN N, EDWARDS ET, CUPPS TR *et al.*: Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. *Arthritis Rheum* 2001; 44: 2862-9.
184. ROBINSON WH, GENOVESE MC, MORELAND LW: Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? *Arthritis Rheum* 2001; 44: 1977-83.
185. SICOTTE NL, VOSKUHL RR: Onset of multiple sclerosis associated with anti-TNF therapy. *Neurology* 2001; 57: 1885-8.
186. JARAND J, ZOCHODNE DW, MARTIN LO, VOLL C: Neurological complications of infliximab. *J Rheumatol* 2006; 33: 1018-20.
187. SUKAL SA, NADIMINTI L, GRANSTEIN RD: Etanercept and demyelinating disease in a patient with psoriasis. *J Am Acad Dermatol* 2006; 54: 160-4.
188. SHIN I-SJ, BAER AN, KWON HJ, PAPA-DOPOULOS EJ, SIEGEL JN: Guillain-Barré and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy. *Arthritis Rheum* 2006; 54: 1429-34.
189. KOTYLA PJ, SLIWINSKA-KOTYLA B, KUCHARZ EJ: Treatment with infliximab may contribute to the development of peripheral neuropathy among the patients with rheumatoid arthritis. *Clin Rheumatol* 2007; 26: 1595-6.
190. TEKTONIDOU MG, SERELIS J, SKOPOULI FN: Peripheral neuropathy in two patients with rheumatoid arthritis receiving infliximab treatment. *Clin Rheumatol* 2007; 26: 258-60.
191. SINGER OC, OTTO B, STEINMETZ H, ZIEMANN U: Acute neuropathy with multiple conduction blocks after TNF-alpha monoclonal antibody therapy. *Neurology* 2004; 63: 1754.
192. COCITO D, BERGAMASCO B, TAVELLA A *et al.*: Multifocal motor neuropathy during treatment with infliximab. *J Peripher Nerv Syst* 2005; 10: 386-7.
193. RODRIGUEZ-ESCALERA C, BELZUNEGUI J, LOPEZ-DOMINGUEZ L, GONZALEZ C, FIGUEROA M: Multifocal motor neuropathy with conduction block in a patient with rheumatoid arthritis on infliximab therapy. *Rheumatology* 2005; 44: 132-3.
194. BIRNBAUM J: Infliximab-associated neuropathy in RA patients--the importance of considering the diagnosis of mononeuritis multiplex. *Clin Rheumatol* 2007; 26: 281-2.
195. RICHELLE P, DIEUDÉ P, DAMIANO J *et al.*: Sensory neuropathy revealing necrotizing vasculitis during infliximab therapy for rheumatoid arthritis. *J Rheumatol* 2004; 31: 2079-81.
196. STÜBGEN J-P: Tumor necrosis factor-alpha antagonists and neuropathy. *Muscle Nerve* 2008; 37: 281-92.
197. YOKOYAMA H, WATANABE T, MARUYAMA D *et al.*: Progressive multifocal leukoencephalopathy in a patient with B-cell lymphoma during rituximab-containing chemotherapy: case report and review of the literature. *Int J Hematol* 2008; 88: 443-7.
198. HARRIS HE: Progressive multifocal leukoencephalopathy in a patient with systemic lupus erythematosus treated with rituximab. *Rheumatology* 2008; 47: 224-5.
199. GUILLEVIN L, MOUTHON L: Tumor necrosis factor-alpha blockade and the risk of vasculitis. *J Rheumatol* 2004; 31: 1885-7.
200. SAINT MARCOUX B, DE BANDT M, CRI (CLUB RHUMATISMES ET INFLAMMATION): Vasculitides induced by TNF-alpha antagonists: a study in 39 patients in France. *Joint Bone Spine* 2006; 73: 710-3.
201. RAMOS-CASALS M, BRITO-ZERÓN P, CUADRADO M-J, KHAMASHTA MA: Vasculitis induced by tumor necrosis factor-targeted therapies. *Curr Rheumatol Rep* 2008; 10: 442-8.
202. LIVERMORE PA, MURRAY KJ: Anti-tumour necrosis factor therapy associated with cutaneous vasculitis. *Rheumatology* 2002; 41: 1450-2.
203. JARRETT SJ, CUNNANE G, CONAGHAN PG *et al.*: Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. *J Rheumatol* 2003; 30: 2287-91.
204. HENNUM J, NACE J, SHAMMASH E, GERTNER E: Infliximab-associated pneumonitis in rheumatoid arthritis. *Rheumatology* 2006; 33: 1917-8.
205. OSTOR AJ, CHILVERS ER, SOMERVILLE MF *et al.*: Pulmonary complications of infliximab therapy in patients with rheumatoid arthritis. *J Rheumatol* 2006; 33: 622-8.
206. QUINTOS-MACASA AM, QUINET R: Enbrel-induced interstitial lung disease. *South Med J* 2006; 99: 783-4.
207. LEON RJ, GONSALVO A, SALAS R, HIDALGO NC: Rituximab-induced acute pulmonary fibrosis. *Mayo Clin Proc* 2004; 79: 949-53.
208. KOIKE T, HARIGAI M, INOKUMA S *et al.*: Post-marketing surveillance of the safety and effectiveness of etanercept in Japan. *J Rheumatol* 2009; 36: 898-906.
209. WOLFE F, CAPLAN L, MICHAUD K: Rheumatoid arthritis treatment and the risk of severe interstitial lung disease. *Scand J Rheumatol* 2007; 36: 172-8.
210. WOLFE F, ZWILLICH SH: The long-term outcomes of rheumatoid arthritis: a 23-year prospective, longitudinal study of total joint replacement and its predictors in 1,600 patients with rheumatoid arthritis. *Arthritis Rheum* 1998; 41: 1072-82.
211. BIBBO C, GOLDBERG JW: Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy. *Foot Ankle Int* 2004; 25: 331-5.
212. ROSANDICH PA, KELLEY JT, CONN DL: Perioperative management of patients with rheumatoid arthritis in the era of biologic response modifiers. *Curr Opin Rheumatol* 2004; 16: 192-8.
213. TALWALKAR SC, GRENNAN DM, GRAY J, JOHNSON P, HAYTON MJ: Tumor necrosis factor alpha antagonists and early postoperative complications in patients with inflammatory joint disease undergoing elective orthopaedic surgery. *Ann Rheum Dis* 2005; 64: 650-1.
214. GILES JT, BARTLETT SJ, GELBER AC *et al.*: Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. *Arthritis Rheum* 2006; 55: 333-7.
215. DEN BROEDER AA, CREEMERS MCW, FRANSEN J *et al.*: Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study. *J Rheumatol* 2007; 34: 689-95.
216. BURT MJ, FRIZELLE FA, BARBEZAT GO: Pregnancy and exposure to infliximab (anti-tumor necrosis factor-alpha monoclonal antibody). *J Gastroenterol Hepatol* 2003; 18: 465-6.
217. KINDER AJ, EDWARDS J, SAMANTA A, NICHOL F: Pregnancy in a rheumatoid arthritis patient on infliximab and methotrexate. *Rheumatology* 2004; 43: 1195-6.
218. MAHADEVAN U, KANE S, SANDBORN WJ *et al.*: Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. *Aliment Pharmacol Ther* 2005; 21: 733-8.
219. SHRIMA A, KOREN G: Tumour necrosis factor alpha and use of infliximab. Safety during pregnancy. *Can Fam Physician* 2005; 51: 667-8.
220. VESGA L, TERDIMAN JP, MAHADEVAN U: Adalimumab use in pregnancy. *Gut* 2005; 54: 890.
221. TURSI A: Effect of intentional infliximab use throughout pregnancy in inducing and maintaining remission in Crohn's disease. *Dig Liver Dis* 2006; 38: 439-40.
222. ROUX CH, BROCCQ O, BREUIL V, ALBERT C, EULLER-ZIEGLER L: Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy. *Rheumatology* 2007; 46: 695-8.
223. SKOMSVOLL JF, WALLENIUS M, KOKSVIK HS *et al.*: Drug insight: Anti-tumor necrosis factor therapy for inflammatory arthropathies during reproduction, pregnancy and lactation. *Nat Clin Pract Rheumatol* 2007; 3: 156-64.
224. NEROME Y, IMANAKA H, NONAKA Y *et al.*: A case of planned pregnancy with an interruption in infliximab administration in a 27-year-old female patient with rheumatoid-factor-positive polyarthritis juvenile idiopathic arthritis which improved after restarting infliximab and methotrexate. *Mod Rheumatol* 2008; 18: 189-92.
225. BERTHELOT J-M, BANDT MD, GOUPILLE P *et al.*: Exposure to anti-TNF drugs during pregnancy: Outcome of 15 cases and review of the literature. *Joint Bone Spine* 2009; 76: 28-34.
226. CARTER JD, LADHANI A, RICCA LR, VALERIANO J, VASEY FB: A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. *J Rheumatol* 2009; 36: 635-41.
227. ØSTENSEN M, LOCKSHIN M, DORIA A *et al.*: Update on safety during pregnancy of bio-

- logical agents and some immunosuppressive anti-rheumatic drugs. *Rheumatology* 2008; 47 (Suppl. 3): iii28-31.
228. VINET E, PINEAU C, GORDON C, CLARKE AE, BERNATSKY S: Biologic therapy and pregnancy outcomes in women with rheumatic diseases. *Arthritis Rheum* 2009; 61: 587-92.
229. CUSH JJ: Biological drug use: US perspectives on indications and monitoring. *Ann Rheum Dis* 2005; 64 (Suppl. 4): iv18-23.
230. CARTER JD, VALERIANO J, VASEY FB: Tumor necrosis factor-alpha inhibition and VATER association: a causal relationship. *J Rheumatol* 2006; 33: 1014-7.
231. KIMBY E, SVERRISDOTTIR A, ELINDER G: Safety of rituximab therapy during the first trimester of pregnancy: a case history. *Eur J Haematol* 2004; 72: 292-5.
232. FRIEDRICH B, TIEMANN M, SALWENDER H *et al.*: The effects of rituximab treatment during pregnancy on a neonate. *Haematologica* 2006; 91: 1426-7.
233. KLINK DT, VAN ELBURG RM, SCHREURS MWJ, VAN WELL GTJ: Rituximab administration in third trimester of pregnancy suppresses neonatal B-cell development. *Clin Dev Immunol* 2008; 2008: 271363.